What is Intellipharmaceutics International Inc. (IPCIF)?

Intellipharmaceutics International Inc. (IPCIF) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of IPCIF?

The current price of IPCIF is $0.15. Prices are updated in real time on Stocks360.

What is IPCIF's price-to-earnings (PE) ratio?

IPCIF's trailing twelve-month PE ratio is -1.72, based on current price and earnings per share data available on Stocks360.

What is IPCIF's market capitalization?

IPCIF's market capitalization is $4,963,905.00, placing it in the small-cap tier.

Intellipharmaceutics International Inc. (IPCIF)

Stock analysis · OTC · Healthcare · Biotechnology

$0.15

Market Cap

$4.96M

PE (TTM)

-1.72

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.40

Day Range

$0.15 – $0.15

52-wk Range

$0.15 – $0.15

Avg Volume

N/A

Volume

0.00

Intellipharmaceutics International Inc. (IPCIF) is a publicly traded company in the Healthcare sector. Latest price: $0.15. Market cap $4.96M. Trailing PE -1.72. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Jul 15, 2021

EPS $-0.04 vs est. $7.47

Missed by $7.51

Proprietary Signals

Signal snapshot temporarily unavailable.

About Intellipharmaceutics International Inc.

Intellipharmaceutics International Inc. operates as a pharmaceutical firm primarily engaged in the research, development, and manufacturing of both novel and generic oral solid dosage medications that feature controlled and targeted release mechanisms. The company's U.S. operations are central to its work. Leveraging its unique and patented Hypermatrix technology, Intellipharmaceutics is dedicated to creating advanced drug delivery systems and cultivating a robust pipeline of product candidates across various therapeutic domains. These include critical areas such as neurological disorders, cardiovascular health, gastrointestinal conditions, diabetes, and pain management. The company's current commercial portfolio includes a variety of extended-release and delayed-release products. These offerings address conditions like hyperactivity disorder (Focalin XR), epilepsy (Keppra XR, Lamictal XR), depression (Effexor XR, Pristiq, Seroquel XR), gastroesophageal reflux disease (Protonix), type 2 diabetes (Glucophage XR), schizophrenia and bipolar disorder (Seroquel XR), heart failure and hypertension (Coreg CR), and chronic angina (Ranexa). Additionally, Intellipharmaceutics is actively pr…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-1.72×
P/S (TTM)	75.52×
P/B	-0.47×
PEG	0.02×
P/FCF (TTM)	-3.58×
EV / EBITDA	-2.73×
EV / Sales	109.64×
Earnings Yield	-58.27%
Free Cash Flow Yield	-27.97%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$7.21M
Revenue (TTM)	$65.73K
Net Income (TTM)	-$2.89M
Free Cash Flow (TTM)	-$1.10M
Net Debt	$2.24M
Working Capital	-$11.52M
Gross Margin	100.00%
Operating Margin	-4336.82%
Net Margin	-4400.55%
Return on Equity	27.35%
Return on Invested Capital	34.55%